Paper Information

Journal:   INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR)   JANUARY 2015 , Volume 9 , Number 1; Page(s) 10 To 14.
 
Paper: 

GDP VERSUS ESHAP REGIMEN IN RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA: A COMPARISON STUDY

 
 
Author(s):  RAMZI MANI, REZVANI ALIRAZA*, DEHGHANI MAHDI
 
* NAMAZI HOSPITAL, DEPARTMENT OF MEDICAL ONCOLOGY AND HEMATOLOGY & BONE MARROW TRANSPLANTATION, SHIRAZ UNIVERSITY OF MEDICAL SCIENCE, ZAND AVENUE, SHIRAZ, IRAN
 
Abstract: 

Background: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin’s lymphoma, there are no comparisons of different combinations. Patients and methods: A Total of 44 patients identified with refractory or relapsed Hodgkin’s Lymphoma were considered eligible for this study. The Patients were randomly divided into two groups of 22, one of which were treated with GDP regimen (gemcitabine, dexamethasone and cisplatin) and the other with EHSAP regimen (etoposide, methyl prednisolone, cisplatin and cytarabine) in a prospective manner. The results of each group were compared.
Results: There were 27.3% complete response, 31.8% more than 50% response, and 40.9% no response with GDP. ESHAP results were 29.5%, 24% and 45.5%, respectively.
Conclusion: There is no significant difference in response rate between GDP and ESHAP regimens as salvage chemotherapy in refractory or relapsed Hodgkin’s Lymphoma.

 
Keyword(s): HODGKIN LYMPHOMA, RELAPSED HODGKIN LYMPHOMA, SALVAGE CHEMOTHERAPY
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 67
 
Latest on Blog
Enter SID Blog